Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed drug for the treatment of certain types of lung cancer. It has been approved in the United States (US) by the Food and Drug Administration (FDA). The approved formulation of the study drug is a capsule. This study will involve  2 new investigational formulations, an investigational liquid formulation, and the approved capsule formulation.

Esomeprazole will also be given in this study. Esomeprazole is similar to Nexium®. It belongs to a group of medications called Proton Pump Inhibitors (PPIs). These medications reduce the amount of stomach acid produced by specific glands in the lining of your stomach. They are used to relieve symptoms of acid reflux (heartburn). They are also used to treat peptic or stomach ulcers and damage to the lower esophagus caused by acid reflux.

You may be eligible if:

  • You are a healthy male or female (unable to bear children) 18-55 years of age
  • You are able to meet all eligibility criteria
  • You are able to comply with all study visits

Study Number: A8081069

Be compensated for your time: up to $8,550.00 for completion of the study

This study involves:

You will be in this study up to about 99 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 6 dosing periods (5 separate admissions)
  • 31 overnight stays total
  • 1 follow-up phone call (28-35 days after the last dose) 

Please review the informed consent document: A8081069 ICD v23May2019

Please review more information about the study: A8081069 Guidelines Restrictions Dates v08May2019